Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 5/20 | 0.44 |
| ▸ | BCR | P11274 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839195 | 0.89 | CA1 (0.43) | PTGS2CA1CA2ABL1BCR | |
| SCHEMBL6839129 | 0.85 | KIF11 (0.49) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL6839726 | 0.85 | PTGS2 (0.55) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL6743053 | 0.85 | PTGS2 (0.41) | PTGS2CA1CA2ABL1BCR | |
| SCHEMBL6836328 | 0.85 | PTGS2 (0.47) | PTGS2CA1CA2PTGS1FFAR1 | |
| SCHEMBL6837154 | 0.85 | CA1 (0.41) | PTGS2CA1CA2PTGS1 | |
| SCHEMBL6838913 | 0.84 | PTGS2 (0.54) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL6839563 | 0.84 | PTGS2 (0.52) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL6840873 | 0.83 | CA2 (0.49) | PTGS2CA1CA2PTGS1CA12 | |
| SCHEMBL6841826 | 0.83 | PTGS2 (0.56) | PTGS2CA1CA2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | PTGS2 10/4885CA1 2085/4885CA2 3175/4885 |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | PTGS2 10/4885CA1 2085/4885CA2 3175/4885 |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | PTGS2 10/4885CA1 2085/4885CA2 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.